Cellectis
Latest round
- Series C
Last raised
- Jun 2005
Total raised
- $14M
Investors
- 4
About Cellectis
Founded in 1999, Cellectis SA operates out of Paris, France, focusing on developing advanced gene-editing therapies for cancer treatment. The CEO, Andre Choulika, has a history of leadership in biotechnology ventures, underscoring the company’s commitment to advancing cancer therapies globally.Cellectis specializes in developing innovative gene-edited CAR T-cell therapies, primarily leveraging its proprietary TALEN® technology platform to create allogeneic 'off-the-shelf' immunotherapy products. These therapies are designed to provide new treatment options for cancer patients, specifically targeting B-cell malignancies like relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell Non-Hodgkin lymphoma. Cellectis' CAR T therapies utilize gene-edited T-cells derived from healthy donors to mitigate challenges associated with traditional CAR T treatments, such as Graft vs. Host Disease and rejection. The company’s offerings, including product candidates like UCART20x22 and UCART22, are aimed at broad patient populations and have been presented at significant scientific conferences, showing active engagement with the global medical community.In 2010, Cellectis reported a revenue of USD 10,836,282, alongside an EBITDA of USD -13,778,241. The company generates revenue through strategic partnerships with pharmaceutical firms such as Allogene and AstraZeneca, likely involving revenue-sharing agreements and milestone payments tied to the development of therapies.Cellectis is focused on expanding its portfolio of gene-edited CAR T-cell therapies, with plans to launch new products designed to address unmet medical needs in oncology.
Who invested in Cellectis
4 investors across 2 rounds
See all investors in Cellectis
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cellectis
Who invested in Cellectis?
Cellectis has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cellectis raised?
Cellectis has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Cellectis last raise money?
Cellectis's most recent round on record is a Series C, in Jun 2005.
What does Cellectis do?
Founded in 1999, Cellectis SA operates out of Paris, France, focusing on developing advanced gene-editing therapies for cancer treatment.
Where is Cellectis headquartered?
Cellectis is headquartered in Paris, France.
Which VCs invest in companies like Cellectis?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Cellectis's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Cellectis? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.